PMID- 25655950
OWN - NLM
STAT- MEDLINE
DCOM- 20150509
LR  - 20150225
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
VI  - 353
IP  - 1
DP  - 2015 Apr
TI  - Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy 
      subjects.
PG  - 102-11
LID - 10.1124/jpet.114.222356 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational 
      drug. The aim of the present study was to explore the role of dopamine in the 
      psychotropic effects of MDMA using bupropion to inhibit the dopamine and 
      norepinephrine transporters through which MDMA releases dopamine and 
      norepinephrine by investigating. The pharmacodynamic and pharmacokinetic 
      interactions between bupropion and MDMA in 16 healthy subjects were investigated 
      using a double-blind, placebo-controlled, crossover design. Bupropion reduced the 
      MDMA-induced elevations in plasma norepinephrine concentrations and the heart 
      rate response to MDMA. In contrast, bupropion increased plasma MDMA 
      concentrations and prolonged its subjective effects. Conversely, MDMA increased 
      plasma bupropion concentrations. These results indicate a role for the 
      transporter-mediated release of norepinephrine in the cardiostimulant effects of 
      MDMA but do not support a modulatory role for dopamine in the mood effects of 
      MDMA. These results also indicate that the use of MDMA during therapy with 
      bupropion may result in higher plasma concentrations of both MDMA and bupropion 
      and enhanced mood effects but also result in lower cardiac stimulation.
CI  - Copyright (c) 2015 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - Schmid, Yasmin
AU  - Schmid Y
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Rickli, Anna
AU  - Rickli A
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Schaffner, Antonia
AU  - Schaffner A
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Duthaler, Urs
AU  - Duthaler U
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Grouzmann, Eric
AU  - Grouzmann E
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Hysek, Cedric M
AU  - Hysek CM
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.).
FAU - Liechti, Matthias E
AU  - Liechti ME
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and 
      Department of Clinical Research, University Hospital Basel, Basel, Switzerland 
      (Y.S., A.R., A.S., U.D., C.M.H., M.E.L.); and Biomedicine Service, University 
      Hospital Lausanne, Lausanne, Switzerland (E.G.) matthias.liechti@usb.ch.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150205
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Norepinephrine Plasma Membrane Transport Proteins)
RN  - 0 (Psychotropic Drugs)
RN  - 01ZG3TPX31 (Bupropion)
RN  - 50-56-6 (Oxytocin)
RN  - 9002-62-4 (Prolactin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adult
MH  - Bupropion/pharmacokinetics/*pharmacology
MH  - Cross-Over Studies
MH  - Dopamine/blood
MH  - Dopamine Plasma Membrane Transport Proteins/metabolism
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Epinephrine/blood
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics/*pharmacology
MH  - Norepinephrine Plasma Membrane Transport Proteins/metabolism
MH  - Oxytocin/blood
MH  - Prolactin/blood
MH  - Psychotropic Drugs/pharmacokinetics/*pharmacology
MH  - Young Adult
EDAT- 2015/02/07 06:00
MHDA- 2015/05/10 06:00
CRDT- 2015/02/07 06:00
PHST- 2015/02/07 06:00 [entrez]
PHST- 2015/02/07 06:00 [pubmed]
PHST- 2015/05/10 06:00 [medline]
AID - jpet.114.222356 [pii]
AID - 10.1124/jpet.114.222356 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2015 Apr;353(1):102-11. doi: 10.1124/jpet.114.222356. Epub 
      2015 Feb 5.